TNF Inhibitors Raise Lymphocyte Counts and Track With Better Survival Across IMIDs
In a large Veterans Affairs cohort, TNF inhibitor therapy was tied to a rise in absolute lymphocyte count, and higher lymphocyte counts were linked to lower all-cause mortality across a broad range of immune-mediated inflammatory diseases. The signal ran through rheumatoid arthritis, psoriasis, inflammatory bowel disease, and ankylosing spondylitis, suggesting that this was not a narrow disease-specific phenomenon. It was a biologically coherent pattern: blockade of TNF, a cytokine central to inflammatory activation, appeared to move lymphocyte counts upward rather than downward. In this analysis, that hematologic shift carried prognostic weight.
The study examined 31,416 patients who began a biologic or targeted synthetic disease-modifying antirheumatic drug between 2017 and 2022 and had complete blood counts before treatment and again 3 to 24 months later. Most of the cohort started TNF inhibition, while smaller groups received IL12/23, IL23, IL17, IL6, costimulation blockade with abatacept, or JAK inhibition. Baseline differences between treatment groups were expected: patients receiving IL6 inhibitors, abatacept, and JAK inhibitors were older and carried more comorbidity, while the distribution of diagnoses followed the usual prescribing patterns for each class. Even so, the central finding did not depend on those class imbalances.
Lymphocyte Gains Followed TNF Blockade More Consistently Than Other Drug Classes
Among 22,471 patients who initiated TNF inhibitor therapy, the mean absolute lymphocyte count increased by 0.23 × 10^3 cells/µL, with a 95% confidence interval of 0.22 to 0.24. In contrast, the non-TNF biologic and targeted synthetic classes did not show the same uniform rise. Some groups were flat, and a few trended slightly downward. The difference was not subtle when the cohorts were modeled together: after adjustment for baseline ALC, demographics, comorbidities, conventional DMARD use, chronic steroid use, and immune-mediated inflammatory disease diagnosis, patients on TNF inhibitors had significantly higher post-treatment ALCs than those starting the other drug classes, with paired ALC differences ranging from 0.18 to 0.29 × 10^3 cells/µL across six comparisons.
One sentence captures the clinical direction of travel: TNF blockade moved lymphocyte counts upward when other advanced therapies generally did not.
That pattern is consistent with TNF’s role in inflammatory cell activation, survival, and apoptosis. Excess TNF signaling can sustain chronic immune stimulation and tissue injury, and in that setting, a low absolute lymphocyte count may function as a marker of ongoing systemic stress rather than a benign laboratory variation. The findings fit with earlier observations in rheumatoid arthritis and psoriatic arthritis showing that lower lymphocyte counts track with higher subsequent mortality, while TNF inhibitor initiation can reverse lymphocytosis and raise ALC. Here, the same relationship appeared across a broader IMID population.
Higher Baseline and Follow-Up ALC Both Mapped to Better Survival
Mortality analysis extended the signal beyond laboratory change. In survival models adjusted for age, race, sex, ethnicity, Charlson comorbidity index, concordant conventional DMARDs, and chronic steroid exposure, TNF inhibitor use, higher baseline ALC, and increased ALC at follow-up were all associated with better survival. The investigators also tested models with potential interactions between treatment class and lymphocyte measures, and the analysis was stratified by IMID to account for different baseline hazards across diseases.
The finding matters because it links a routine, inexpensive laboratory test to a hard endpoint. Absolute lymphocyte count is not a specialized biomarker reserved for research settings; it sits in the standard complete blood count. In this cohort, a higher count was not simply a reflection of healthier patients at baseline. It remained associated with survival after adjustment for multiple clinical variables. In practical terms, a rise in ALC after TNF blockade may reflect better control of inflammatory burden, a recovery from immune dysregulation, or both.
The Cohort Was Broad, but the Signal Still Favored TNF Inhibition
The patient mix was large and clinically heterogeneous. Mean age was 58 years across the full cohort, and men made up 86% of the sample, consistent with the VA population. White patients comprised 76% of the cohort, Black patients 14%, and 7.1% identified as Hispanic or Latino. Mean Charlson comorbidity burden was 1.65 overall, but it was higher in the IL6 inhibitor, abatacept, and JAK inhibitor groups. Concomitant methotrexate, leflunomide, sulfasalazine, azathioprine, and chronic corticosteroid use varied by drug class, reflecting how treatment selection is woven into disease phenotype and prior therapy history.
Pre-treatment ALC was lower in the older treatment groups, including IL6 inhibitors, abatacept, and JAK inhibitors. Even with those differences in age and comorbidity, the TNF inhibitor group stood apart for the direction and size of its lymphocyte change. Among the biologic and targeted synthetic therapies evaluated, TNF inhibition was the clearest driver of increased ALC.
What the Biology Suggests at the Bedside
The biologic logic is straightforward. TNF sits high in the inflammatory cascade, shaping innate and adaptive immune activity and amplifying tissue injury in diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. If TNF-driven inflammation suppresses or redistributes lymphocytes during active disease, then effective TNF blockade could allow lymphocyte counts to recover toward a healthier steady state. That recovery may be the laboratory footprint of reduced systemic inflammation, improved immune homeostasis, or diminished catabolic stress.
A second possibility is more cautious and clinically important: the ALC rise may be a prognostic biomarker rather than a causal mediator. The study design cannot settle that question. Retrospective data can show association, and this analysis did so with careful adjustment, but it cannot prove that changing ALC itself improves survival. It can, however, identify a cheap and accessible marker that may help clinicians think more carefully about treatment response and underlying physiologic reserve.
The mortality signal was assessed through July 2025, giving the cohort at least 2 years of follow-up and, for early enrollees, more than 8 years. That length of observation strengthens the survival analysis, but it also leaves room for residual confounding, treatment selection bias, and disease severity differences that administrative data cannot fully capture. Diagnoses were identified through VA data sources, blood counts were measured in routine practice, and treatment exposure was defined by fills or injections. Those are pragmatic strengths. They are also the reason the findings should be interpreted as real-world association rather than causal proof.
The most actionable takeaway is narrow and concrete: in a large IMID population, TNF inhibitor therapy was associated with an increase in absolute lymphocyte count, and both higher baseline ALC and rising ALC tracked with lower mortality after adjustment for major clinical factors. Whether the lymphocyte shift is part of the mechanism of improved survival or simply a marker of it remains unresolved, and the answer will require prospective work that can separate biological effect from prognostic signal.